Article

Gamma vinyl-GABA differentially modulates NMDA antagonist-induced increases in mesocortical versus mesolimbic DA transmission.

Chemistry Department, Brookhaven National Laboratory, Upton, NY 11973, USA.
Neuropsychopharmacology (impact factor: 7.99). 12/2001; 25(5):704-12. DOI:10.1016/S0893-133X(01)00268-8 pp.704-12
Source: PubMed

ABSTRACT To explore the role of endogenous GABA in NMDA antagonist induced dopamine (DA) release, we used in vivo microdialysis to study the effects of pretreatment with gamma-vinyl GABA (GVG) on phencyclidine (PCP)-induced DA release in terminal regions of midbrain DA neurons. GVG, an irreversible inhibitor of the GABA catabolizing enzyme GABA-AT, significantly reduced the DA response to PCP (7.0 mg/kg) in freely moving animals. Preferential increases in PCP-induced DA release in the PFC (four-fold those of NAcc) were dose-dependently inhibited by acute pretreatment with GVG at doses of 150 (51% inhibition), 300 (68% inhibition), and 500 (82% inhibition) mg/kg, whereas NAcc PCP-induced DA activity was unresponsive to 150 mg/kg and only partially inhibited by 300 and 500 mg/kg. Subchronic treatment with GVG did not enhance the inhibitory capacity of the GABAergic system. While GVG evidently modulates PCP-induced increases in mesocorticolimbic DA transmission, the character of this modulation is regionally specific, with cortical NMDA-antagonist induced increases appearing more sensitive to inhibition by endogenous GABA than subcortical areas.

0 0
 · 
0 Bookmarks
 · 
15 Views
  • Source
    Article: Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    [show abstract] [hide abstract]
    ABSTRACT: It has been postulated that disturbances in glutamatergic transmission may contribute to the pathophysiology of schizophrenia. This view is based on several findings: (1) the noncompetitive NMDA receptor antagonists, phencyclidine and ketamine, induce both positive and negative psychotic symptoms in humans, which closely resemble those observed in schizophrenia; (2) a number of animal studies have shown that neuroleptics that ameliorate symptoms of schizophrenia (e.g. clozapine) also inhibit the effects of NMDA antagonists; (3) postmortem and in vivo studies have revealed alterations in ionotropic glutamate receptors (NMDA, AMPA, KA) and their modulatory sites in schizophrenia; (4) compounds enhancing the function of NMDA receptors potentiate the antipsychotic effects of neuroleptics in schizophrenic patients.
    Polish journal of pharmacology 55(2):133-54.

Keywords

51% inhibition
 
68% inhibition
 
82% inhibition
 
acute pretreatment
 
cortical NMDA-antagonist induced increases
 
DA response
 
endogenous GABA
 
GABA catabolizing enzyme GABA-AT
 
inhibition
 
inhibitory capacity
 
mesocorticolimbic DA transmission
 
midbrain DA neurons
 
NAcc PCP-induced DA activity
 
NMDA antagonist induced dopamine
 
PCP)-induced DA release
 
PCP-induced DA release
 
PFC
 
Preferential increases
 
Subchronic treatment
 
subcortical areas